INS and metabolic dysfunction-associated steatotic liver disease: The beneficial pharmacological effects of GLP1/GLP-1RAs include increasing insulin secretion, suppressing glucagon release, slowing gastric emptying, and enhancing satiety, resulting in an improvement in glucose and lipid metabolism, as well as weight loss, reduced cardiovascular risk factors, and the improvement of non-alcoholic fatty liver disease NAFLD [34,35,36,37,38,39].